Table 2.
Univariate and multivariate proportional hazard analyses of cancer‐specific survival (n = 106)
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% index | P‐values | Hazard ratio | 95% index | P‐values | |
| Serum PSA (ng/dL) (≥10 vs <10) | 1.02 | 0.32–3.26 | 0.98 | 1.39 | 0.39–5.01 | 0.6 |
| Gleason score (≥8 vs≤7) | 17.2 | 3.34–314 | 0.0001 | 7.63 | 0.94–168 | 0.06 |
| Pathological T stage (≥3b vs≤3a) | 11.4 | 2.99–74.3 | 0.0002 | 2.38 | 0.42–20.9 | 0.34 |
| Pathological N stage (1 vs 0) | 5.29 | 1.56–16.6 | 0.0094 | 1.01 | 0.26–3.69 | 0.98 |
| ERRs (high ERRα and low ERRγvs low ERRα and high ERRγ or others) | 23.2 | 3.73–173 | 0.0006 | 15.2 | 1.65–186 | 0.015 |
We divided the data into three groups on the basis of immunoreactivity: high ERRα and low ERRγ, low ERRα and high ERR and other immunoreactivity groups. ERR, estrogen‐related receotor; PSA, prostate‐specific antigen.